PhD Defence Fernanda Marques Câmara Sodré

June 29, 2021
We warmly congratulate Fernanda Sodré on the successful defense of her PhD thesis, 'The role of the post-translational modification citrullination in type 1 diabetes.' Her work sheds new light on the mechanisms of type 1 diabetes and represents an important step forward in our understanding of the disease. This achievement was made possible under the guidance of Chantal Mathieu (promoter), Mijke Buitinga (co-promoter), and Lut Overbergh (co-promoter) with the support and evaluation of the examination committee: Annemieke Verstuyf (chairman), Paul Proost (Rega Institute, KU Leuven, Leuven, Belgium), Ben Sprangers (UZ Leuven, Leuven, Belgium), Alessandra Kupper Cardoso (Université Libre de Bruxelles (ULB), Brussels, Belgium), and Arnaud Zaldumbide (Leids Universitair Medisch Centrum (LUMC), Leiden, The Netherlands). We celebrate this milestone and wish Dr. Sodré every success in the next chapter of her scientific career.
Share this post

PhD Research Summary - Dr. Fernanda Sodré

Type 1 diabetes is caused by the immune system attacking and destroying the insulin-producing beta cells of the pancreas, but the exact trigger remains unclear. In her PhD, Fernanda Sodré investigated the role of citrullination, a post-translational modification of proteins mediated by PAD enzymes.

Her work demonstrated that citrullinated GRP78, previously identified as an autoantigen in non-obese diabetic (NOD) mice, is also an autoantigen in human type 1 diabetes. Importantly, blocking citrullination in NOD mice prevented diabetes development, and vaccination with a citrullinated GRP78 peptide reduced diabetes incidence.

These findings highlight citrullination as a key player in type 1 diabetes and open new perspectives for therapeutic intervention.

More information can be found via the link.

Support us

Choose to make a direct impact by contributing to a specific research project or by supporting the overarching goals of the Hippo & Friends Type 1 Diabetes Fund. 

By donating today, you enable early-career scientists to pursue groundbreaking research aimed at preventing and curing type 1 diabetes.
Every contribution moves us one step closer to breakthroughs that matter.